Expertise in
15
conditions

Dr. Hillel Tobias

Hepatology
North Shore-Lij Medical PC
100 E 77th St, 
New York, NY 
59 Years of Experience
Expertise in
15
conditions
North Shore-Lij Medical PC
100 E 77th St, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Hillel Tobias is a Hepatologist in New York, New York. Dr. Tobias has been practicing medicine for over 59 years is highly rated in 15 conditions, according to our data. His top areas of expertise are Hepatitis, Hepatitis C, Visceromegaly, Non-Alcoholic Fatty Liver Disease, and Liver Transplant.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hepatology
Licenses
Internal Medicine in NY
Hospital Affiliations
Lenox Hill Hospital
Nyu Langone Hospitals
North Shore University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northwell Health
  • INSURANCE PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

NORTH SHORE-LIJ MEDICAL PC
100 E 77th St, New York, NY 10075

Additional Areas of Focus

Dr. Tobias has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: August 02, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: May 18, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Terminated
Publish Date: November 25, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

2 Total Publications

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).
Journal: Hepatology (Baltimore, Md.)
Published: September 04, 2015
Similar Doctors
Expertise in
20
conditions
Dr. Ira Jacobson
Hepatology
Expertise in
20
conditions
Dr. Ira Jacobson
Hepatology

New York University

530 1st Ave, 
New York, NY 
 (2.3 miles away)
212-263-7300
Experience:
46+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ira Jacobson is a Hepatologist in New York, New York. Dr. Jacobson has been practicing medicine for over 46 years is highly rated in 20 conditions, according to our data. His top areas of expertise are Hepatitis, Hepatitis C, Cirrhosis, Liver Transplant, and Endoscopy.

Douglas Dieterich
Expertise in
23
conditions
Dr. Douglas Dieterich
Hepatology
Expertise in
23
conditions
Dr. Douglas Dieterich
Hepatology

Icahn School Of Medicine At Mount Sinai

5 E 98th St, Fl 12, 
New York, NY 
 (1.1 miles away)
212-659-8086
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Douglas Dieterich is a Hepatologist in New York, New York. Dr. Dieterich is highly rated in 23 conditions, according to our data. His top areas of expertise are Hepatitis, Hepatitis C, Cirrhosis, Non-Alcoholic Fatty Liver Disease, and Liver Transplant.

Expertise in
31
conditions
Dr. Thomas Schiano
Hepatology
Expertise in
31
conditions
Dr. Thomas Schiano
Hepatology

Icahn School Of Medicine At Mount Sinai

579 Franklin Tpke, 
Ridgewood, NJ 
 (16.5 miles away)
201-251-3485
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thomas Schiano is a Hepatologist in Ridgewood, New Jersey. Dr. Schiano is highly rated in 31 conditions, according to our data. His top areas of expertise are Hepatitis, Hepatitis C, Autoimmune Hepatitis, Liver Transplant, and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tobias's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 8 Advanced Conditions
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile